# Bath & Body Works, Inc. (BBWI) — Financial Analysis

**Exchange:**   
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-10  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/BBWI/thesis · /stocks/BBWI/memo

## Financial Snapshot

---
source: coverage-next-full
step: 04
ticker: BBWI
company: Bath & Body Works, Inc.
date: 2026-06-10
---

### Step 04 — Financial Snapshot & Quality Assessment
**Bath & Body Works, Inc. (BBWI)**
*Source: coverage-next-full | No earnings transcripts used*

---

#### 1. Income Statement Quality

##### Revenue Recognition
BBWI recognizes revenue at point of sale (store) or upon shipment/pickup (direct). Loyalty program reward redemption is deferred; revenue is recognized when points are redeemed or expire [S1]. No complex multi-element arrangements. Revenue recognition is straightforward for a specialty retailer.

**Quality assessment: HIGH** — Simple, at-point-of-sale recognition; no channel stuffing risk given owned stores; loyalty deferred revenue is appropriately handled.

##### Gross Margin Adjustments

| Item | Amount | Direction | Note |
|------|--------|-----------|------|
| Buying & Occupancy Expenses | Included in COGS | — | BBWI includes occupancy in gross margin calculation |
| Tariff impact (FY2025) | ~-60bps | Negative | Management-cited driver; not a one-off |
| Fulfillment center exit (Q1 FY2025) | Small positive | One-time benefit | Exited third-party fulfillment contract |

**Adjusted Gross Margin (FY2025):** 43.7% GAAP. No material adjustments needed — this is an appropriately-burdened gross margin inclusive of occupancy.

##### SG&A Adjustments

| Item | FY2025 ($M) | Classification |
|------|-------------|----------------|
| CEO/executive severance (Boswell) | $15M | Transformation cost; arguably one-time |
| Business transformation charges | $14M | Consumer First Formula setup |
| **Adjusted SG&A** | $2,063M - $29M = **$2,034M** | Adj. SG&A = 27.9% of sales |

**Adjusted Operating Income (FY2025):** $1,156M (15.8% margin) vs. GAAP $1,126M (15.4%) [S1]

##### Interest Expense
$276M (FY2025) on $3.9B average debt at 7.1% average rate [S1]. Fixed-rate notes; interest expense will decline as debt is repaid. FY2026: redemption of 2027 Notes ($289M) → ~$19M annual interest savings.

##### Effective Tax Rate
FY2025: 26.4% (vs. FY2024: 22.4%). FY2024 rate was lower due to $44M valuation allowance release on Easton investment. **Normalized rate: 26-27%.** FY2025 is the better benchmark [S1].

---

#### 2. Balance Sheet Quality

##### Cash & Liquidity
- Cash: $953M (Jan 31, 2026); $210M held by foreign subs [S1]
- ABL Facility: $750M commitment; $473M available; zero drawn [S1]
- Effective liquidity: ~$1.4B
- **Quality: Strong** — no near-term liquidity risk

##### Negative Equity Analysis

BBWI has had negative stockholders' equity since approximately FY2012. This is a **structural artifact**, not a distress signal:

Root causes:
1. L Brands' aggressive share repurchases pre-spin (>$5B cumulative) depleted equity base
2. Spin-off in 2021 allocated substantial L Brands debt to BBWI (VSCO received less leverage)
3. BBWI has continued buybacks post-spin ($4.2B FY2021-FY2025) which further depleted equity
4. Accumulated deficit of $(1,435M) as of Jan 31, 2026

**Key test:** BBWI generates $865M+ FCF and services $276M in annual interest comfortably. Cash interest coverage ratio: $1,126M EBIT ÷ $276M = 4.1x. **Solvency is not at risk.**

##### Debt Quality

| Note | Coupon | Maturity | Face Value |
|------|--------|----------|------------|
| 2027 Notes | 6.694% | Jan 2027 | $284M |
| 2028 Notes | 5.250% | Feb 2028 | $444M |
| 2029 Notes | 7.500% | Jun 2029 | $482M |
| 2030 Notes | 6.625% | Oct 2030 | $844M |
| 2035 Notes | 6.875% | Nov 2035 | $802M |
| 2036 Notes | 6.750% | Jul 2036 | $575M |
| 2033 Debentures | 6.950% | Mar 2033 | $284M |
| 2037 Notes | 7.600% | Jul 2037 | $201M |

*[S1] No covenants that constrain operations (ABL covenant only triggers below $70M availability). No floating-rate debt in the note structure.*

---

#### 3. Cash Flow Quality

| Metric | FY2025 | FY2024 | FY2023 | Notes |
|--------|--------|--------|--------|-------|
| Net Income | $649M | $798M | $878M | |
| Operating CF | $1,102M | $886M | $954M | |
| OCF / Net Income | 1.70x | 1.11x | 1.09x | Non-cash items + working capital |
| FCF | $865M | $660M | $656M | |
| FCF / Net Income | 1.33x | 0.83x | 0.75x | |
| SBC ($M) | $31M | $40M | $43M | Small; minimal dilution |
| D&A ($M) | $254M | $282M | — | |

**FY2025 FCF strength is high quality:** OCF of $1,102M includes $649M net income + $254M D&A + $31M SBC + $63M deferred tax + $111M working capital benefit (favorable AP/accruals timing) [S1]. The working capital benefit is partly cyclical (inventory draw-down as BBWI ran cautious inventory); some reversal in FY2026 is possible.

**FY2026 FCF guidance: ~$600M** — implying ~$265M FCF decline from FY2025. Drivers: revenue decline → lower OCF; $289M 2027 Note redemption impacts cash (but classified as financing). Capex guidance $270M (vs $237M FY2025). The guided decline is real but manageable.

---

#### 4. Adversarial Research Sweep

*Note: Earnings transcripts not available. This section is based on public investigations, short reports, lawsuits, and adverse media from web research and SEC filings.*

##### Short Thesis / Bear Arguments in Market

From analyst commentary and public bear case [S4]:
1. **Brand relevance erosion:** Management's own admission of underperforming the sector (not just macro) suggests the brand is losing appeal vs. Ulta and beauty alternatives. Not merely a macro story.
2. **CFO departure (June 12, 2026):** Eva Boratto departing simultaneously with new CEO in Year 1 of transformation = operational risk. No CFO named at time of 10-K filing [S1].
3. **Leverage at sub-investment grade:** Ba2/BB+ credit ratings; debt trades near par but any operational deterioration could pressure refinancing. FY2026 FCF guidance $600M suggests less cash for debt repayment.
4. **Revenue momentum:** Q1 FY2026 revenue -3.2% YoY despite easy comp (Q1 FY2025 was already weak). Guidance midpoint implies full-year -3.5% — further revenue attrition.
5. **Historical guidance-beating record weak:** FY2025 management acknowledged "did not meet our expectations" [S1] — first explicit guidance miss language.

##### Material Lawsuits / Investigations

From available SEC filings and public records:
- **Product liability:** Standard for personal care/cosmetics; no material reported litigation [S1]
- **Employment class actions:** BBWI disclosed standard employment-related matters in legal proceedings section; no material individual cases [S1]
- **No accounting investigations, SEC inquiries, or restatements** identified in filings
- **Tariff compliance:** No regulatory actions

**Adversarial Assessment:** The primary bear thesis is operational and strategic (brand relevance, transformation risk) rather than fraud, accounting irregularities, or legal/regulatory risk. Financial quality is solid.

---

#### 5. Key Ratios Summary

| Metric | FY2025 | FY2024 | FY2023 |
|--------|--------|--------|--------|
| Gross Margin | 43.7% | 44.3% | 43.6% |
| Operating Margin | 15.4% | 17.3% | 17.3% |
| Net Margin | 8.9% | 10.9% | 11.8% |
| EBITDA Margin | 18.9% | 21.2% | — |
| FCF Margin | 11.9% | 9.0% | 8.8% |
| OCF / Revenue | 15.1% | 12.1% | 12.8% |
| Interest Coverage (EBIT/Interest) | 4.1x | 4.1x | 3.7x |
| Cash / Debt | 24.5% | 17.3% | 24.7% |
| Capex / Revenue | 3.3% | 3.1% | 4.0% |
| SBC / Revenue | 0.4% | 0.5% | 0.6% |

*[S1][S2][S3]*

---

#### Source Index

| ID | Source | Description |
|----|--------|-------------|
| S1 | SEC EDGAR 10-K FY2025 (filed 2026-03-12) | Financial statements, MD&A, legal proceedings |
| S2 | SEC EDGAR XBRL (CIK 0000701985) | Historical financials |
| S3 | StockAnalysis.com (retrieved 2026-06-10) | EBITDA, quarterly data, multiples |
| S4 | Analyst consensus/notes (retrieved 2026-06-10) | Bear case articulation |

*Note: Earnings transcript analysis not performed. Management commentary from 10-K MD&A only.*

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/BBWI/fundamental

## Navigation

- Overview: /stocks/BBWI
- Financials (this page): /stocks/BBWI/financials
- Thesis: /stocks/BBWI/thesis
- Investment Memo: /stocks/BBWI/memo
- Coverage universe: /stocks